Hypertension
Conditions
Brief summary
Study to assess the effect of Telmisartan on diastolic and systolic blood pressure and to establish the effect on patient's quality of life scores.
Interventions
Sponsors
Boehringer Ingelheim
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 93 Years
Healthy volunteers
No
Inclusion criteria
* Patients with Stage I essential Hypertension (diastolic blood pressure 90-99 mmHg, and/or systolic blood pressure 140-159 mmHg) * Signed informed consent form
Exclusion criteria
\- Females of childbearing potential
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in diastolic blood pressure | Pre-dose, up to 6 weeks after start of treatment |
| Change in systolic blood pressure | Pre-dose, up to 6 weeks after start of treatment |
| Changes from baseline in the quality of life (QOL) scores by patient self-assessment | Pre-dose, 6 weeks after start of treatment |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline in pulse pressure | Pre-dose, up to 6 weeks after start of treatment |
| Assessment of blood pressure control rate | Up to 6 weeks after start of treatment |
| Number of patients with adverse events | Up to 6 weeks |
| Assessment of systolic blood pressure response rate | Up to 6 weeks after start of treatment |
| Assessment of diastolic blood pressure response rate | Up to 6 weeks after start of treatment |
Outcome results
None listed